







### ABOUT BANGLADESH

- Strategic hub in South Asia linking India, China, and ASEAN countries
- 5-year GDP growth at a CAGR of 7%, one of the fastest growing economies in the world
- 41st largest economy, poised to become the world's 25th largest economy by 2035
- 10.5% annual growth in country's middle & affluent class population, projected to reach 34 million by 2025

## ACCOLADES & CREDENTIALS

- A 'Next-11' country, Bangladesh is poised to become one of the largest economies of the 21st century, according to Goldman Sachs
- · Credit rating of BB- by Standard & Poor in 2021 indicates long-term stability
- As per JETRO survey on Business Conditions of Japanese Companies, 70% of surveyed firms present in Bangladesh want further 'expansion'





## PHARMACEUTICALS & API SECTOR AT A GLANCE

Bangladesh's pharmaceutical sector contributes to

2% of GDP



# 6 BILLION

Over 140 Countries

Import
BANGLADESHI
medicine, including
USA, UK, AUSTRALIA,
CANADA



of the domestic demand is met by local producers

- Branded generic drugs account for 80% of drugs produced locally
- Global market for generic drugs is projected to grow at a CAGR of 8% to reach USD 578 billion by 2023
- As much as 97.3% of APIs are imported from nations like India, China and South Korea

With a current market size of USD 730 million, domestic API market is projected to reach 1.4 billion by 2025

capsule shells
and significant amount of
packaging materials
are IMPORTED DUE
TO HIGH-TECH
PROCESSING
requirement

### DEMAND DRIVERS

LARGE DOMESTIC MARKET WITH INCREASING INCOME AND HEALTH **AWARENESS** 

Opportunities for **FURTHER** INVESTMENT



in generic drugs since drugs worth more than \$150 billion are coming off patent by 2021 and another **USD 250** BILLION by 2023

Changing disease profile: Disease patterns **RAPIDLY SHIFTING** to Non-communicable Diseases such as Cancer, Diabetes, Heart Disease etc., which requires LONG TERM TREATMENT AND **MEDICATION** 



INTERNATIONAL **ACCREDITATIONS** are on the rise for Bangladeshi Pharmaceutical companies

### **GROWTH DRIVERS**



10% to 15% LOWER COST of production than India and China



Availability of SKILLED **PROFESSIONALS** with expertise in manufacturing generic drugs



WTO

extended patent waiver from TRIPS until 2033 which is favorable for **GENERIC DRUG PRODUCTION** 

- API production is encouraged through attractive fiscal incentives and export subsidies
- National API/ Laboratory Reagents Production and Export Policy 2018 aims to attract investment worth USD 1 billion, reduce import-dependence, raise API export income and create 500,000 jobs by 2032
- 200-acre API Park established in Munshigani, close to capital Dhaka

# INCENTIVES AND POLICIES

#### **Fiscal Incentives-Income Tax**

- Active Pharmaceuticals Ingredients (API) and laboratory reagent producers, registered in Bangladesh will enjoy 100% corporate tax holiday until 2021-22.
- After 2021-22, Active Pharmaceuticals Ingredients (API) and laboratory reagent producers, will further enjoy tax holiday (from 2023-2032) if they could produce API molecules domestically:
- For 5 API molecules producers will get 100% tax holiday
- For 3 API molecules producers will get 75% tax holiday.
- No AIT will be applicable for API producers on import of chemical compounds (Technical Grade/Chemically pure).
- Firms established between July 1, 2019 and June 30, 2024 are eligible or phased or partial tax exemption from 5 up to 10 years.

#### **Eligible Industries:**

- API and radio-pharmaceuticals,
- Pharmaceuticals,
- Barrier contraceptive and rubber latex.

#### **Conditions:**

- Paid-up capital of not less than BDT 2 million on the date of beginning of commercial production.
- 30% of the exempted has to be reinvested in the same or other industrial undertakings within one year.

#### **Export Cash Incentives**

20% export subsidy on exporting Active Pharmaceuticals Ingredients (API) from Bangladesh

10% export subsidy on exporting pharmaceuticals products



















KPMG



